← Back to Search

Tyrosine Kinase Inhibitor

Targeted Therapy for Advanced Cancer (MyTACTIC Trial)

Phase 2
Waitlist Available
Research Sponsored by Genentech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Positive biomarker results from a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory and availability of a full report of the testing results. This may be from a tissue or blood sample.
In addition to the general inclusion criteria above, there are treatment-specific inclusion criteria that apply for each respective treatment arm (as detailed in the protocol)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

MyTACTIC Trial Summary

This trial will test new targeted therapies for safety and efficacy in patients with advanced, unresectable solid tumors. Patients will be enrolled based on the presence of specific biomarkers, and will be treated with a drug or drug regimen tailored to their individual biomarker profile.

Who is the study for?
This trial is for adults with advanced, inoperable or metastatic solid tumors that have specific biomarkers. Participants must have a confirmed diagnosis, positive biomarker results from an accredited lab, measurable disease, be relatively stable physically (ECOG 0-2), expected to live at least 8 weeks, and have good organ function. They should not be pregnant and agree to prevent pregnancy.Check my eligibility
What is being tested?
The study tests targeted therapies like Tucatinib and Atezolizumab among others as single agents or combinations based on tumor biomarkers. It's non-randomized and open-label meaning everyone knows what treatment they're getting. The goal is to see how safe and effective these treatments are when matched to the tumor's genetic profile.See study design
What are the potential side effects?
Potential side effects include reactions related to the immune system such as inflammation of organs due to drugs like Atezolizumab; nerve damage from drugs like Paclitaxel; liver issues from Ipatasertib; heart problems from Trastuzumab-based therapies; fatigue, nausea, blood disorders can also occur.

MyTACTIC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My test results, from a certified lab, show a positive biomarker.
Select...
I meet the specific requirements for my chosen treatment option.
Select...
My blood and organ tests meet the study's requirements.
Select...
My cancer is advanced, cannot be surgically removed, and has spread.
Select...
I can take care of myself and am up and about more than half of my waking hours.

MyTACTIC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants with Confirmed Overall Response, as Assessed by the Investigator According to RECIST v1.1 or According to RANO Criteria for Primary CNS Tumors
Secondary outcome measures
Duration of Response, as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0)
Percentage of Participants with Disease Control, as Determined by the Investigator According to RECIST v1.1 or RANO Criteria
+2 more

MyTACTIC Trial Design

15Treatment groups
Experimental Treatment
Group I: Arm O: PralsetinibExperimental Treatment1 Intervention
Participants in this treatment arm must have a positive tumor biomarker result for RET fusion.
Group II: Arm N: Atezolizumab + TiragolumabExperimental Treatment2 Interventions
Participants in this treatment arm must have a positive tumor biomarker result for either TMB high or MSI high/dMMR.
Group III: Arm M: Ipatasertib + PaclitaxelExperimental Treatment2 Interventions
Participants in this treatment arm must have a positive tumor biomarker results for PI3KCA activating mutations and either AKT1/2/3 activating mutation or PTEN loss/loss of function.
Group IV: Arm L: Ipatasertib + AtezolizumabExperimental Treatment2 Interventions
Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
Group V: Arm K: Ipatasertib + AtezolizumabExperimental Treatment2 Interventions
Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
Group VI: Arm J: Trastuzumab Emtansine + AtezolizumabExperimental Treatment2 Interventions
Participants in this treatment arm must have positive tumor biomarker results for ERBB2 mutation or amplification and TMB high or MSI high/dMMR.
Group VII: Arm I: Trastuzumab Emtansine + TucatinibExperimental Treatment2 Interventions
Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
Group VIII: Arm H: PH FDC SC + Investigator's Choice of ChemotherapyExperimental Treatment2 Interventions
Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
Group IX: Arm G: PH FDC SCExperimental Treatment1 Intervention
Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutation or amplification without known TMB high or MSI high/dMMR.
Group X: Arm F: Trastuzumab Emtansine + AtezolizumabExperimental Treatment2 Interventions
Participants in this treatment arm must have a positive tumor biomarker result for ERBB2 mutations or amplification without known TMB high or MSI high/dMMR.
Group XI: Arm E: Atezolizumab + Investigator's Choice of ChemotherapyExperimental Treatment2 Interventions
Participants in this treatment arm must have a positive tumor biomarker result for either tumor mutational burden (TMB) high or microsatellite instability (MSI) high/deficient mismatch repair (dMMR).
Group XII: Arm D: IpatasertibExperimental Treatment1 Intervention
Participants in this treatment arm must have a positive tumor biomarker result for either AKT1/2/3 activating mutation or PTEN loss/loss of function.
Group XIII: Arm C: AlectinibExperimental Treatment1 Intervention
Participants in this treatment arm must have a positive tumor biomarker result for ALK rearrangement tumors.
Group XIV: Arm B: InavolisibExperimental Treatment1 Intervention
Participants in this treatment arm must have a positive tumor biomarker result for PI3KCA activating mutation.
Group XV: Arm A: EntrectinibExperimental Treatment1 Intervention
Participants in this treatment arm must have a positive tumor biomarker result for ROS1 gene fusion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Investigator's Choice of Chemotherapy
2021
Completed Phase 2
~260
Alectinib
2015
Completed Phase 3
~2400
Tucatinib
2017
Completed Phase 2
~520
Ipatasertib
2019
Completed Phase 3
~2340
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
2021
Completed Phase 2
~260
Inavolisib
2021
Completed Phase 2
~260
Paclitaxel
2011
Completed Phase 4
~5380
Trastuzumab Emtansine
2016
Completed Phase 3
~5630
Pralsetinib
2021
Completed Phase 2
~260
Atezolizumab
2016
Completed Phase 3
~6040
Tiragolumab
2020
Completed Phase 2
~350
Entrectinib
2014
Completed Phase 2
~360

Find a Location

Who is running the clinical trial?

Genentech, Inc.Lead Sponsor
1,538 Previous Clinical Trials
567,428 Total Patients Enrolled
Clinical TrialsStudy DirectorGenentech, Inc.
2,197 Previous Clinical Trials
888,308 Total Patients Enrolled

Media Library

Alectinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04632992 — Phase 2
Cancer Research Study Groups: Arm H: PH FDC SC + Investigator's Choice of Chemotherapy, Arm I: Trastuzumab Emtansine + Tucatinib, Arm F: Trastuzumab Emtansine + Atezolizumab, Arm N: Atezolizumab + Tiragolumab, Arm E: Atezolizumab + Investigator's Choice of Chemotherapy, Arm M: Ipatasertib + Paclitaxel, Arm J: Trastuzumab Emtansine + Atezolizumab, Arm L: Ipatasertib + Atezolizumab, Arm O: Pralsetinib, Arm D: Ipatasertib, Arm G: PH FDC SC, Arm K: Ipatasertib + Atezolizumab, Arm A: Entrectinib, Arm B: Inavolisib, Arm C: Alectinib
Cancer Clinical Trial 2023: Alectinib Highlights & Side Effects. Trial Name: NCT04632992 — Phase 2
Alectinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04632992 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you provide me with a summary of any supplemental research related to Tiragolumab?

"Tiragolumab was first researched back in 1997 at the City of Hope Comprehensive Cancer Center. At present, a total of 1580 clinical trials have been finished, with 1352 ongoing across numerous locations - primarily Modesto, California."

Answered by AI

Are recruitment efforts underway to include participants in this experiment?

"Data sourced from clinicaltrials.gov indicates that this medical trial is not presently seeking new candidates, despite having been posted initially on January 13th 2021 and last updated on September 8th 2022. With 3,732 other trials recruiting participants at present, however, there are plenty of opportunities available for those interested in taking part in a clinical study."

Answered by AI

How many medical institutions are conducting this trial currently?

"46 medical centres across the United States are presently enrolling patients for this trial. Major cities that are included in these locations include Modesto, Boise and Sacramento; however, there is a plethora of other sites to choose from closer to home if you opt-in."

Answered by AI

To what maladies is Tiragolumab typically applied?

"Tiragolumab is frequently used to mitigate metastatic bladder cancer, as well as inflammatory breast cancer (IBC), small cell lung cancer (SCLC) and other malignant neoplasms."

Answered by AI

How many participants is the maximum capacity for this clinical trial?

"Sadly, this trial is no longer recruiting. It was first introduced on the 13th of January 2021 and last updated on 8th September 2022. If you are researching other trials, there are 2380 studies reliant upon cancer patients and another 1352 for Tiragolumab that still need participants."

Answered by AI

Has Tiragolumab been accepted by the FDA for use in treatments?

"Despite there being no evidence of its efficacy, the safety profile of Tiragolumab has been assessed to be a 2 due to some preliminary data."

Answered by AI

Who else is applying?

What state do they live in?
California
What site did they apply to?
Kaiser Permanente Medical Ctr
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
3+
~60 spots leftby Mar 2025